

Johnson & Johnson Statement On IARC (Updated)

July 5, 2024 - Attributable to Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson:

“IARC does not cite any recent study, and there is none, that supports its speculative assertion that all talc is “probably” carcinogenic. In fact, IARC acknowledges that the new epidemiology study undertaken by Katie O’Brien, one of the IARC panelists, does not warrant a revised designation. IARC’s reclassification, which is not a causal conclusion, is unfounded and inconsistent with the FDA’s consistent findings for years that talc does not cause cancer. It is an irresponsible act by an organization that has repeatedly fomented meritless litigation in the United States with sweeping and unsubstantiated pronouncements. J&J continues to stand by the safety of its talc products and calls on anyone interested in these issues to review the actual science, which overwhelmingly supports the view that talc is safe and does not cause cancer.”

###